durvalumab + tremelimumab + vinorelbine

This is a combination therapy consisting of three drugs: durvalumab, tremelimumab, and vinorelbine. Durvalumab is a human monoclonal antibody targeting programmed death-ligand 1 (PD-L1), acting as an immune checkpoint inhibitor to enhance anti-tumor immune responses. Tremelimumab is a fully human IgG2 monoclonal antibody that targets cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), another immune checkpoint, further promoting T cell-mediated tumor destruction. Vinorelbine is a semi-synthetic vinca alkaloid chemotherapy agent that inhibits microtubule assembly, disrupting mitosis in cancer cells. This combination has been investigated in phase I/II clinical trials for advanced solid tumors, including advanced cervical cancer and breast cancer, showing promising antitumor activity and manageable safety profiles[1][2][8]. The regimen leverages both immunotherapy and chemotherapy mechanisms to improve outcomes in patients with refractory or recurrent cancers.

Other names

MEDI4736MEDI-4736MEDI 4736ticilimumab